These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36549710)

  • 1. Cytokines as prognostic biomarkers in pulmonary arterial hypertension.
    Boucly A; Tu L; Guignabert C; Rhodes C; De Groote P; Prévot G; Bergot E; Bourdin A; Beurnier A; Roche A; Jevnikar M; Jaïs X; Montani D; Wilkins MR; Humbert M; Sitbon O; Savale L
    Eur Respir J; 2023 Mar; 61(3):. PubMed ID: 36549710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Right Heart Network and Risk Stratification in Pulmonary Arterial Hypertension.
    Haddad F; Contrepois K; Amsallem M; Denault AY; Bernardo RJ; Jha A; Taylor S; Arthur Ataam J; Mercier O; Kuznetsova T; Vonk Noordegraaf A; Zamanian RT; Sweatt AJ
    Chest; 2022 May; 161(5):1347-1359. PubMed ID: 34774527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension.
    Rhodes CJ; Wharton J; Howard LS; Gibbs JS; Wilkins MR
    Heart; 2011 Jul; 97(13):1054-60. PubMed ID: 21558476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis.
    Hoeper MM; Pausch C; Olsson KM; Huscher D; Pittrow D; Grünig E; Staehler G; Vizza CD; Gall H; Distler O; Opitz C; Gibbs JSR; Delcroix M; Ghofrani HA; Ewert R; Kaemmerer H; Kabitz HJ; Skowasch D; Behr J; Milger K; Halank M; Wilkens H; Seyfarth HJ; Held M; Dumitrescu D; Tsangaris I; Vonk-Noordegraaf A; Ulrich S; Klose H; Claussen M; Eisenmann S; Schmidt KH; Rosenkranz S; Lange TJ
    J Heart Lung Transplant; 2022 Jul; 41(7):971-981. PubMed ID: 35430147
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noninvasive Prognostic Biomarkers for Left-Sided Heart Failure as Predictors of Survival in Pulmonary Arterial Hypertension.
    Simpson CE; Damico RL; Hassoun PM; Martin LJ; Yang J; Nies MK; Vaidya RD; Brandal S; Pauciulo MW; Austin ED; Ivy DD; Nichols WC; Everett AD
    Chest; 2020 Jun; 157(6):1606-1616. PubMed ID: 31987881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using the Plasma Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension.
    Rhodes CJ; Wharton J; Swietlik EM; Harbaum L; Girerd B; Coghlan JG; Lordan J; Church C; Pepke-Zaba J; Toshner M; Wort SJ; Kiely DG; Condliffe R; Lawrie A; Gräf S; Montani D; Boucly A; Sitbon O; Humbert M; Howard LS; Morrell NW; Wilkins MR
    Am J Respir Crit Care Med; 2022 May; 205(9):1102-1111. PubMed ID: 35081018
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of changes in NT-proBNP, hsTnT and uric acid levels with haemodynamic changes after targeted medical therapies in patients with idiopathic pulmonary arterial hypertension.
    Li WT; Wu CW; Liu JM
    Cardiovasc J Afr; 2022 Jan-Feb 23; 33(1):10-14. PubMed ID: 34851353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of B-type natriuretic peptides in the assessment of patients with systemic sclerosis-associated pulmonary hypertension in the PHAROS registry.
    Chung L; Fairchild RM; Furst DE; Li S; Alkassab F; Bolster MB; Csuka ME; Derk CT; Domsic RT; Fischer A; Frech TM; Gomberg-Maitland M; Gordon JK; Hinchcliff M; Hsu V; Hummers LK; Khanna D; Medsger TAJ; Molitor JA; Preston IR; Schiopu E; Shapiro L; Hant F; Silver R; Simms R; Varga J; Steen VD; Zamanian RT
    Clin Exp Rheumatol; 2017; 35 Suppl 106(4):106-113. PubMed ID: 27908301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Significance of Biomarkers in Pulmonary Arterial Hypertension.
    Al-Naamani N; Palevsky HI; Lederer DJ; Horn EM; Mathai SC; Roberts KE; Tracy RP; Hassoun PM; Girgis RE; Shimbo D; Post WS; Kawut SM;
    Ann Am Thorac Soc; 2016 Jan; 13(1):25-30. PubMed ID: 26501464
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of N-Terminal Pro Brain Natriuretic Peptide and Long-Term Outcome in Patients With Pulmonary Arterial Hypertension.
    Chin KM; Rubin LJ; Channick R; Di Scala L; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF
    Circulation; 2019 May; 139(21):2440-2450. PubMed ID: 30982349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Iron Deficiency on Clinical and Haemodynamic Parameters in Pulmonary Arterial Hypertension Cohorts.
    Saluja P; Gautam N; Amisha F; Salah HM; Smith J; Biyani S; Venkata AN; Al'Aref SJ; Jagana R
    Heart Lung Circ; 2022 Dec; 31(12):1594-1603. PubMed ID: 36402703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension.
    Wronski SL; Mordin M; Kelley K; Anguiano RH; Classi P; Shen E; Manaker S
    Lung; 2020 Feb; 198(1):65-86. PubMed ID: 31722043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide in pediatric patients with pulmonary arterial hypertension.
    Takatsuki S; Wagner BD; Ivy DD
    Congenit Heart Dis; 2012; 7(3):259-67. PubMed ID: 22325151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension.
    Fijalkowska A; Kurzyna M; Torbicki A; Szewczyk G; Florczyk M; Pruszczyk P; Szturmowicz M
    Chest; 2006 May; 129(5):1313-21. PubMed ID: 16685024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study.
    Thakkar V; Stevens WM; Prior D; Moore OA; Byron J; Liew D; Patterson K; Hissaria P; Roddy J; Zochling J; Sahhar J; Nash P; Tymms K; Celermajer D; Gabbay E; Youssef P; Proudman SM; Nikpour M
    Arthritis Res Ther; 2012 Jun; 14(3):R143. PubMed ID: 22691291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan.
    Rotondo C; Praino E; Nivuori M; di Serio F; Lapadula G; Iannone F
    Int J Rheum Dis; 2017 Jan; 20(1):90-96. PubMed ID: 26218502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of brain natriuretic peptides in patients with pulmonary arterial hypertension: A systematic review and meta-analysis.
    Hendriks PM; van de Groep LD; Veen KM; van Thor MCJ; Meertens S; Boersma E; Boomars KA; Post MC; van den Bosch AE
    Am Heart J; 2022 Aug; 250():34-44. PubMed ID: 35533723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guideline implementation and early risk assessment in pulmonary arterial hypertension associated with congenital heart disease: A retrospective cohort study.
    Deng X; Jin B; Li S; Li Y; Zhou H; Wu Y; Yan M; Hu Y; Qiu Q; Zhang G; Zheng X
    Clin Respir J; 2019 Nov; 13(11):693-699. PubMed ID: 31419027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension.
    Weatherald J; Boucly A; Chemla D; Savale L; Peng M; Jevnikar M; Jaïs X; Taniguchi Y; O'Connell C; Parent F; Sattler C; Hervé P; Simonneau G; Montani D; Humbert M; Adir Y; Sitbon O
    Circulation; 2018 Feb; 137(7):693-704. PubMed ID: 29070502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic profiling of in vivo right ventricular function and exercise performance in pulmonary arterial hypertension.
    Simpson CE; Coursen J; Hsu S; Gough EK; Harlan R; Roux A; Aja S; Graham D; Kauffman M; Suresh K; Tedford RJ; Kolb TM; Mathai SC; Hassoun PM; Damico RL
    Am J Physiol Lung Cell Mol Physiol; 2023 Jun; 324(6):L836-L848. PubMed ID: 37070742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.